132 related articles for article (PubMed ID: 10516413)
21. Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. The ATLAS Study Group.
Sculpher MJ; Poole L; Cleland J; Drummond M; Armstrong PW; Horowitz JD; Massie BM; Poole-Wilson PA; Ryden L
Eur J Heart Fail; 2000 Dec; 2(4):447-54. PubMed ID: 11113723
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study.
McInnes G; Burke TA; Carides G
J Hum Hypertens; 2006 Jan; 20(1):51-8. PubMed ID: 16357874
[TBL] [Abstract][Full Text] [Related]
23. ACE inhibitors still the drug of choice for heart failure--and more.
Topol E
Lancet; 1999 Nov; 354(9192):1797. PubMed ID: 10577651
[No Abstract] [Full Text] [Related]
24. Cost effectiveness of ACE inhibitor treatment for patients with type 1 diabetes mellitus.
Dong FB; Sorensen SW; Manninen DL; Thompson TJ; Narayan V; Orians CE; Gregg EW; Eastman RC; Dasbach EJ; Herman WH; Newman JM; Narva AS; Ballard DJ; Engelgau MM
Pharmacoeconomics; 2004; 22(15):1015-27. PubMed ID: 15449965
[TBL] [Abstract][Full Text] [Related]
25. Comparison of losartan and captopril in ELITE II.
Lye M
Lancet; 2000 Sep; 356(9232):852; author reply 852-3. PubMed ID: 11022949
[No Abstract] [Full Text] [Related]
26. A multi-center, double-blind, randomized, parallel group study to evaluate the effects of two different doses of losartan on morbidity and mortality in Chinese patients with symptomatic heart failure intolerant of angiotensin converting enzyme inhibitor treatment.
Hu DY; Huang J; Cai NS; Zhu WL; Li YS; Massaad R; Hanson ME; Dickstein K
Chin Med J (Engl); 2012 Nov; 125(21):3868-74. PubMed ID: 23106890
[TBL] [Abstract][Full Text] [Related]
27. New competition in the realm of renin-angiotensin axis inhibition; the angiotensin II receptor antagonists in congestive heart failure.
Martineau P; Goulet J
Ann Pharmacother; 2001 Jan; 35(1):71-84. PubMed ID: 11197588
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of losartan versus atenolol in treating hypertension--an analysis of the LIFE study from a Swiss perspective.
Szucs TD; Burnier M; Erne P
Cardiovasc Drugs Ther; 2004 Sep; 18(5):391-7. PubMed ID: 15717142
[TBL] [Abstract][Full Text] [Related]
29. Comparison of losartan and captopril in ELITE II.
Hall A
Lancet; 2000 Sep; 356(9232):851; author reply 852-3. PubMed ID: 11022946
[No Abstract] [Full Text] [Related]
30. Comparison of losartan and captopril in ELITE II.
Meyer FP
Lancet; 2000 Sep; 356(9232):851; author reply 852-3. PubMed ID: 11022947
[No Abstract] [Full Text] [Related]
31. Comparison of baseline data, initial course, and management: losartan versus captopril following acute myocardial infarction (The OPTIMAAL Trial). OPTIMAAL Trial Steering Committee and Investigators. Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan.
Dickstein K; Kjekshus J;
Am J Cardiol; 2001 Mar; 87(6):766-71, A7. PubMed ID: 11249900
[TBL] [Abstract][Full Text] [Related]
32. Early and chronic captopril or Losartan therapy reduces infarct size and avoids congestive heart failure after myocardial infarction in rats.
MartÃnez LA; Villalobos-Molina R
Arch Med Res; 2003; 34(5):357-61. PubMed ID: 14602500
[TBL] [Abstract][Full Text] [Related]
33. The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model.
Pradelli L; Iannazzo S; Zaniolo O
Am J Cardiovasc Drugs; 2009; 9(6):383-92. PubMed ID: 19929036
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of captopril therapy after myocardial infarction.
Tsevat J; Duke D; Goldman L; Pfeffer MA; Lamas GA; Soukup JR; Kuntz KM; Lee TH
J Am Coll Cardiol; 1995 Oct; 26(4):914-9. PubMed ID: 7560617
[TBL] [Abstract][Full Text] [Related]
35. [Angiotensin receptor antagonist for therapy of patients with hypertension].
Rakugi H; Ogihara T
Nihon Rinsho; 1997 Aug; 55(8):2075-80. PubMed ID: 9284426
[TBL] [Abstract][Full Text] [Related]
36. [Effect of long-term treatment with enalapril, losartan and their combination on the quality of life of patients with congestive heart failure].
Vizir VA; Berezin AE
Ter Arkh; 2002; 74(1):52-5. PubMed ID: 11878061
[TBL] [Abstract][Full Text] [Related]
37. Erythropoietin levels in heart failure after an acute myocardial infarction: determinants, prognostic value, and the effects of captopril versus losartan.
Belonje AM; Westenbrink BD; Voors AA; von Haehling S; Ponikowski P; Anker SD; van Veldhuisen DJ; Dickstein K
Am Heart J; 2009 Jan; 157(1):91-6. PubMed ID: 19081402
[TBL] [Abstract][Full Text] [Related]
38. Design of the heart failure endpoint evaluation of AII-antagonist losartan (HEAAL) study in patients intolerant to ACE-inhibitor.
Konstam MA; Poole-Wilson PA; Dickstein K; Drexler H; Justice SJ; Komajda M; Malbecq W; Martinez FA; Neaton JD; Riegger GA; Guptha S
Eur J Heart Fail; 2008 Sep; 10(9):899-906. PubMed ID: 18768350
[TBL] [Abstract][Full Text] [Related]
39. Pharmacoeconomics of angiotensin converting enzyme inhibitors in heart failure.
Szucs TD
Am J Hypertens; 1997 Oct; 10(10 Pt 2):272S-279S. PubMed ID: 9366284
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure.
Weintraub WS; Zhang Z; Mahoney EM; Kolm P; Spertus JA; Caro J; Ishak J; Goldberg R; Tooley J; Willke R; Pitt B
Circulation; 2005 Mar; 111(9):1106-13. PubMed ID: 15723981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
